-1752955012230.webp&w=3840&q=75)
2025 NOSCM | Kidney Cancer: Novel Development in Targeted and Immunotherapy
Overview
Dr. Primo Lara reviewed kidney cancer therapies, noting surgery as standard for Stage 1 with high survival. For Stages 2-3, adjuvant pembrolizumab improves outcomes. Metastatic cases use nivo-ipi or pembro-axi combos. He stressed risk-based, individualized care and ongoing trials for future options.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Primo Lara, Jr., MD, FASCO
Date of Release
July 20th, 2025
-1755991286446.webp&w=3840&q=75)
-1755991157601.webp&w=3840&q=75)